Mankind Pharma Ltd

However, revenue from operations increased 23.9% year on year (YoY) to Rs 3,230 crore in the third quarter of FY25. Profit before tax was at Rs 497.33 crore in Q3 of FY25, registering a de-growth of 11.56% from Rs 562.32 crore recorded in Q3 FY24. EBITDA grew 36.4% YoY to Rs 833 crore in the December 2024 quarter. EBITDA margin improved to 25.8% in Q3 FY25 as compared to 23.4% recorded in the corresponding quarter previous year. Domestic revenue stood at Rs 2,773 crore in Q3 FY25, up by 15.5% YoY, while export revenue stood at Rs 457 crore, up by 120.8% YoY during the quarter. Export growth was driven by an increase in base business, supported by new launches in the last 12'24 months and consolidation of BSV. During the quarter, the company has launched 1 new product in the US, taking the total launched products to 42. The company's consumer healthcare business reported 30% increase in revenue to Rs 193 crore in Q3 FY25, supported by steady growth across all key brands; strong growth in secondary sales for Manforce Condom, Gas-o-fast and HealthOk of 13%, 28% and 26% YoY respectively and gaining strong traction in recent strategic launches: Manforce Epic (Premium category), Nimulid (Pain Management), etc. Cash flow from operations stood at Rs 460 crore in the third quarter of FY25. Rajeev Juneja, vice chairman & managing director, Mankind Pharma, said, 'We achieved a healthy revenue growth of 24% YoY with a strong adjusted EBITDA margin of 27.7% in Q3 FY25, driven by continued outperformance in chronic, strong recovery in OTC and consolidation of BSV. 30% YoY revenue growth in OTC business supported by strategic initiatives undertaken last year. The integration of BSV is on track, with focus on mandate brands, improving productivity and adopting best practices to ensure long term sustainable growth. 2024 has been a transformative year - now having multiple building blocks ' steady base business, fast growing specialty chronic segment, high potential OTC business, and high-entry barrier super specialty portfolio of BSV.' Mankind Pharma is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence.Mankind pharma operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company has 25 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Powered by Capital Market - Live

Net profit of Mankind Pharma declined 16.20% to Rs 380.23 crore in the quarter ended December 2024 as against Rs 453.76 crore during the previous quarter ended December 2023. Sales rose 23.90% to Rs 3230.00 crore in the quarter ended December 2024 as against Rs 2606.95 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales3230.002606.95 24 OPM %25.6923.26 - PBDT689.63672.04 3 PBT497.33562.32 -12 NP380.23453.76 -16 Powered by Capital Market - Live

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 23 January 2025.Powered by Capital Market - Live

Mankind Pharma has allotted 1,19,04,761 equity shares of face value of Re 1 each to the eligible Qualified Institutional Buyers at the issue price of Rs 2,520/- per equity share, i.e. at a premium of Rs 2519/- per equity share aggregating to Rs 2999.99 crore pursuant to the QIP issue. Consequent to the aforesaid allotment, the paid-up share capital of the Company has increased from Rs 40,06,62,138 consisting 40,06,62,138 equity shares to Rs 41,25,66,899 consisting 412566899 equity shares having face value of Re. 1/- each. Powered by Capital Market - Live

The company has approved the allocation of 1,19,04,761 equity shares at an issue price of Rs 2,520 per equity share to the eligible qualified institutional buyers. The issue price represents a discount of 3.69% to the floor price of Rs 2616.55 per equity share. The company has raised an aggregate sum of Rs 2,999.99 crore from the said issue. Consequent to the aforesaid allotment, the paid-up share capital of the company has increased from Rs 40.06 crore consisting 40.06 crore equity shares to Rs 41.25 crore consisting 41.25 crore equity shares having face value of Re 1 each. The QIP attracted significant interest from various institutional investors, including SBI Mutual Fund, Government Pension Fund Global, HDFC Trustee Company, Motilal Oswal Midcap Fund, Government of Singapore, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund, NPS Trust, and Aditya Birla Sun Life Trustee. Mankind pharma is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence.Mankind pharma operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company has 25 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. The company's consolidated net profit surged 30.43% to Rs 653.47 crore on a 13.6% rise in revenue to Rs 3,076.51 crore in Q2 FY25 as compared to Q2 FY24. The scrip shed 0.98% to currently trade at Rs 2861.05 on the BSE. Powered by Capital Market - Live

The company's board authorized and declared the opening of the issue on Monday, 16 December 2024. The floor price of Rs 2,616.55 is at a discount of 2.76% to the scrip's previous closing price of Rs 2,690.80 on the BSE. The company expects to raise a sum of Rs 3,000 crore from the said issue. The company may offer a discount of not more than 5% on the floor price so calculated for the issue. The issue price will be determined in consultation with the book running lead manager appointed for the issue. Mankind Pharma intends to use the issue from the proceeds for repayment / pre-payment of certain outstanding borrowings by the company; and for general corporate purposes. Mankind pharma is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence.Mankind pharma operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company has 25 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. The company's consolidated net profit surged 30.43% to Rs 653.47 crore on a 13.6% rise in revenue to Rs 3,076.51 crore in Q2 FY25 as compared to Q2 FY24. Powered by Capital Market - Live

Mankind Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 2609.95, up 1.9% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.22% on the day, quoting at 24184. The Sensex is at 79872.83, up 0.09%. Mankind Pharma Ltd has slipped around 4.44% in last one month. Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has slipped around 0.69% in last one month and is currently quoting at 22240.2, up 1.08% on the day. The volume in the stock stood at 1.42 lakh shares today, compared to the daily average of 3.47 lakh shares in last one month.The PE of the stock is 51.21 based on TTM earnings ending September 24.Powered by Capital Market - Live

Mankind Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 2537.6, down 3.22% on the day as on 12:59 IST on the NSE. The benchmark NIFTY is down around 0.94% on the day, quoting at 23659.1. The Sensex is at 78018.99, down 0.83%.Mankind Pharma Ltd has lost around 8.04% in last one month.Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has eased around 7.95% in last one month and is currently quoting at 22151.6, down 1.6% on the day. The volume in the stock stood at 2.1 lakh shares today, compared to the daily average of 3.25 lakh shares in last one month.The PE of the stock is 52.54 based on TTM earnings ending September 24.Powered by Capital Market - Live

Mankind Pharma has received reaffirmation in credit ratings from CRISIL as under: Commercial paper (Rs 5,000 crore) - CRISIL A1+ Non convertible debentures (Rs 4,600 crore) - CRISIL AA+/ Stable Non convertible debentures (Rs 400 crore) - CRISIL AA+/ Stable Total bank loan facilities rated (Rs 1,250 crore) - CRISIL AA+/ Stable Powered by Capital Market - Live

Net profit of Mankind Pharma rose 30.43% to Rs 653.47 crore in the quarter ended September 2024 as against Rs 501.03 crore during the previous quarter ended September 2023. Sales rose 13.60% to Rs 3076.51 crore in the quarter ended September 2024 as against Rs 2708.10 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales3076.512708.10 14 OPM %27.6325.21 - PBDT954.94737.48 29 PBT849.32640.99 33 NP653.47501.03 30 Powered by Capital Market - Live